140 related articles for article (PubMed ID: 34911831)
21. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.
Dichtelmüller HO; Biesert L; Fabbrizzi F; Gajardo R; Gröner A; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Pifat D; Osheroff W; Poelsler G
Transfusion; 2009 Sep; 49(9):1931-43. PubMed ID: 19497061
[TBL] [Abstract][Full Text] [Related]
22. Characterization of ionic strength for X-MuLV inactivation by low pH treatment for monoclonal antibody purification.
Daya J; Cusick V; Mattila J
Biotechnol Bioeng; 2023 Jun; 120(6):1605-1613. PubMed ID: 36924035
[TBL] [Abstract][Full Text] [Related]
23. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
24. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
Roberts PL; Lloyd D; Marshall PJ
Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
[TBL] [Abstract][Full Text] [Related]
25. Virus inactivation at moderately low pH varies with virus and buffer properties.
Joshi PU; Meingast CL; Xu X; Holstein M; Feroz H; Ranjan S; Ghose S; Li ZJ; Heldt CL
Biotechnol J; 2022 Feb; 17(2):e2100320. PubMed ID: 34874097
[TBL] [Abstract][Full Text] [Related]
26. Effect of manufacturing process parameters on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate.
Roberts PL; Dunkerley C
Vox Sang; 2003 Apr; 84(3):170-5. PubMed ID: 12670365
[TBL] [Abstract][Full Text] [Related]
27. Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment.
Seitz H; Blümel J; Schmidt I; Willkommen H; Löwer J
Biologicals; 2002 Sep; 30(3):197-205. PubMed ID: 12217344
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of "Nereid," a new phenol-free detergent to replace Triton X-100 in virus inactivation.
Farcet JB; Kindermann J; Karbiener M; Scheinecker R; Kostner O; Kreil TR
J Med Virol; 2021 Jun; 93(6):3880-3889. PubMed ID: 33274764
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products.
Remington KM; Trejo SR; Buczynski G; Li H; Osheroff WP; Brown JP; Renfrow H; Reynolds R; Pifat DY
Vox Sang; 2004 Jul; 87(1):10-8. PubMed ID: 15260817
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
Cipriano D; Burnham M; Hughes JV
Methods Mol Biol; 2012; 899():277-92. PubMed ID: 22735960
[TBL] [Abstract][Full Text] [Related]
31. Characterization of operating parameters for XMuLV inactivation by low pH treatment.
Chinniah S; Hinckley P; Connell-Crowley L
Biotechnol Prog; 2016; 32(1):89-97. PubMed ID: 26488618
[TBL] [Abstract][Full Text] [Related]
32. Proceedings of the 2009 Viral Clearance Symposium.
Miesegaes G; Bailey M; Willkommen H; Chen Q; Roush D; Blümel J; Brorson K
Dev Biol (Basel); 2010; 133():3-101. PubMed ID: 21516942
[TBL] [Abstract][Full Text] [Related]
33. Proceedings of the 2019 Viral Clearance Symposium, Session 8. Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments and Actions.
Bolton G
PDA J Pharm Sci Technol; 2022; 76(4):362-367. PubMed ID: 34911826
[TBL] [Abstract][Full Text] [Related]
34. Proceedings of the 2019 Viral Clearance Symposium, Session 3: Continuous Processing.
Lute S; Specht R
PDA J Pharm Sci Technol; 2022; 76(4):315-322. PubMed ID: 34911830
[TBL] [Abstract][Full Text] [Related]
35. Solvent-induced virus inactivation by acidic arginine solution.
Tsujimoto K; Uozaki M; Ikeda K; Yamazaki H; Utsunomiya H; Ichinose M; Koyama AH; Arakawa T
Int J Mol Med; 2010 Mar; 25(3):433-7. PubMed ID: 20127049
[TBL] [Abstract][Full Text] [Related]
36. Extraction of Triton X-100 and its determination in virus-inactivated human plasma by the solvent--detergent method.
Strancar A; Raspor P; Schwinn H; Schütz R; Josic D
J Chromatogr A; 1994 Jan; 658(2):475-81. PubMed ID: 8118553
[TBL] [Abstract][Full Text] [Related]
37. West Nile Virus inactivation by the solvent/detergent steps of the second and third generation manufacturing processes for B-domain deleted recombinant factor VIII.
Jakubik JJ; Vicik SM; Tannatt MM; Kelley BD
Haemophilia; 2004 Jan; 10(1):69-74. PubMed ID: 14962223
[TBL] [Abstract][Full Text] [Related]
38. Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS.
Biesert L; Suhartono H
Vox Sang; 1998; 74 Suppl 1():207-12. PubMed ID: 9789530
[TBL] [Abstract][Full Text] [Related]
39. Removal of detergent and solvent from solvent-detergent-treated immunoglobulins.
Trescec A; Simić M; Branović K; Gebauer B; Benko B
J Chromatogr A; 1999 Aug; 852(1):87-91. PubMed ID: 10480233
[TBL] [Abstract][Full Text] [Related]
40. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies.
Johnston A; Uren E; Johnstone D; Wu J
Biologicals; 2003 Sep; 31(3):213-21. PubMed ID: 12935811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
